John Trojanowski, 75, a Giant in the Field of Neuropathology
In a career that spanned more than 40 years, Trojanowski broadened and deepened the field's understanding of the molecular pathology of neurodegenerative diseases.
6458 RESULTS
Sort By:
In a career that spanned more than 40 years, Trojanowski broadened and deepened the field's understanding of the molecular pathology of neurodegenerative diseases.
The decision will curtail access until efficacy is shown. Many Alzheimer’s researchers call it a reasonable compromise, others question how it will work in practice.
Other scientists found indications of potentially doctored western blots in multiple papers, including several on Aβ*56. Investigations are underway at journals, NIH, UMinnesota.
In a career spanning four decades, Davies spearheaded the cholinergic hypothesis, unlocked secrets of tau, and readily shared antibodies in the field.
Biogen got the go-ahead under the FDA’s accelerated approval pathway, which requires change in a surrogate biomarker and Phase 4 studies to verify a clinical benefit.
Schenk loses two-year battle with pancreatic cancer.
Drug sponsors Eisai and Biogen said they will apply for approval in Europe, the U.S., and Japan; more detailed data will be presented at CTAD.
Meaningfulness must account for the disease stage a patient is at, his or her priorities, and effects over time, researchers say.
Pancreatic cancer felled the man who led groundbreaking research on astrocytes, oligodendrocytes, and microglia.
Wagner pioneered γ-secretase modulators to treat Alzheimer’s disease, with a candidate slated to enter Phase 1 trials later this year.
As shocked researchers notify each other privately, the Alzforum editors are saddened to inform the community at large that Mark Smith died last Sunday...
The antibody slowed decline by 35 percent, met secondary endpoints, will likely be approved. Major question: How to avoid severe ARIA.
Stalwart of dementia neuropathology was best known for his work on tau pathology.
Futility analysis predicts failure to reach primary endpoint.
In its national coverage determination, Medicare limits Aduhelm coverage to clinical trials, but OKs registry-based studies for traditionally approved anti-Aβ antibodies. This may change once new efficacy data comes out.
No filters selected